Cited by 940Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, Jackson G., Kuhns, Michael S., Allison, James P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Integrity signals

Registry

Crossref · 10.1038/ni0702-611

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Show all 93 references

Sorted by citations

Items 101–200 of 940

Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells
Berger, C. L., Tigelaar, R. E., Cohen, J. V., Mariwalla, K., Trinh, J., Wang, N., & Edelson, R. L. (2004) · Blood · doi:10.1182/blood-2004-06-2181 · Cited by 242
Spatial and Temporal Dynamics of T Cell Receptor Signaling with a Photoactivatable Agonist
Huse, M., Klein, L. O., Girvin, A. T., Faraj, J. M., Li, Q.-J., Kuhns, M. S., & Davis, M. M. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.017 · Cited by 236
Self-citation
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Lee, H. T., Lee, S. H., & Heo, Y. (2019) · Molecules · doi:10.3390/molecules24061190 · Cited by 244
Antibodies, Fc receptors and cancer
Nimmerjahn, F., & Ravetch, J. V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.005 · Cited by 241
Race, Ancestry, and Genes: Implications for Defining Disease Risk
Kittles, R. A., & Weiss, K. M. (2003) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.4.070802.110356 · Cited by 233
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C. R., Diab, A. K., Hymes, S. R., Duvic, M. A., Hwu, W., Wargo, J. A., Torres-Cabala, C. A., et al. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 235
Next Generation of Immunotherapy for Melanoma
Kirkwood, J. M., Tarhini, A. A., Panelli, M. C., Moschos, S. J., Zarour, H. M., Butterfield, L. H., & Gogas, H. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6423 · Cited by 232
The innate immune response to tumors and its role in the induction of T‐cell immunity
Diefenbach, A., & Raulet, D. H. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18802.x · Cited by 228
The multifaceted immune regulation of bladder cancer
Schneider, A. K., Chevalier, M. F., & Derré, L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0226-y · Cited by 222
Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM
Murphy, T. L., & MURPHY, K. M. M. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101202 · Cited by 226
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
Madan, R. A., Arlen, P. M., Mohebtash, M., Hodge, J. W., & Gulley, J. L. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902997928 · Cited by 222
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
Aglietta, M., Barone, C. A., Sawyer, M. B., Moore, M. J., Miller, W. H., Bagalá, C., Colombi, F., Cagnazzo, C., Gioeni, L., Wang, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu205 · Cited by 221
Mechanisms of immune evasion in bladder cancer
Crispen, P. L., & Kusmartsev, S. A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02443-4 · Cited by 221
Expansion and activation of CD4+CD25+ regulatory T cells in Heligmosomoides polygyrus infection
Finney, C. A. M., Taylor, M. D., Wilson, M. S., & Maizels, R. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636751 · Cited by 231
Spatiotemporal Basis of CTLA-4 Costimulatory Molecule-Mediated Negative Regulation of T Cell Activation
Yokosuka, T., Kobayashi, W., Takamatsu, M., Sakata-Sogawa, K., Zeng, H., Hashimoto, A. S., Yagita∥, H., Tokunaga, M., & Saito, T. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.006 · Cited by 224
Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway
Cheung, T. C., Humphreys, I. R., Potter, K. G., Norris, P. S., Shumway, H. M., Tran, B. R., Patterson, G., Jean-Jacques, R., Yoon, M., Spear, P. G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506172102 · Cited by 211
Genome-wide analysis of the structure of the South African Coloured Population in the Western Cape
de Wit, E., Delport, W., Chimusa, E. R., Meintjes, A., Möller, M., van Helden, P. D., Seoighe, C., & Hoal, E. G. (2010) · Human Genetics · doi:10.1007/s00439-010-0836-1 · Cited by 228
Cancer Vaccines: Moving Beyond Current Paradigms
Schlom, J., Arlen, P. M., & Gulley, J. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0588 · Cited by 205
Levallois Lithic Technology from the Kapthurin Formation, Kenya: Acheulian Origin and Middle Stone Age Diversity
Tryon, C. A., McBrearty, S., & Texier, P.-J. (2006) · African Archaeological Review · doi:10.1007/s10437-006-9002-5 · Cited by 203
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
de Gruijl, T. D., van den Eertwegh, A. J. M., Pinedo, H. M., & Scheper, R. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0536-z · Cited by 201
Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Sarnaik, A. A., Yu, B., Yu, D., Morelli, D., Hall, M. S., Bogle, D., Yan, L. E., Targan, S., Solomon, J. C., Nichol, G. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2463 · Cited by 200
Methodological challenges of genome-wide association analysis in Africa
Teo, Y., Small, K. S., & Kwiatkowski, D. P. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2731 · Cited by 202
Differential response of murine CD4+CD25+ and CD4+CD25– T cells to dexamethasone‐induced cell death
Chen, X., Murakami, T., Oppenheim, J. J., & Howard, O. M. Z. (2004) · European Journal of Immunology · doi:10.1002/eji.200324506 · Cited by 195
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci
Cao, K., Moormann, A. M., Lyke, K. E., Masaberg, C., Sumba, O. P., Doumbo, O. K., Koech, D., Lancaster, A. K., Nelson, M. P., Meyer, D., et al. (2004) · Tissue Antigens · doi:10.1111/j.0001-2815.2004.00192.x · Cited by 194
CCL2 Blockade Augments Cancer Immunotherapy
Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S. K., Crisanti, M. C., Wang, L. S., Heitjan, D. F., Snyder, L. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2326 · Cited by 193
Group 2 innate lymphoid cells and CD 4 + T cells cooperate to mediate type 2 immune response in mice
Drake, L. Y., Iijima, K., & Kita, H. (2014) · Allergy · doi:10.1111/all.12446 · Cited by 191
The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells
Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 190
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
He, B., Dong, D., She, Y., Zhou, C., Fang, M., Zhu, Y., Zhang, H., Huang, Z., Jiang, T., Tian, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000550 · Cited by 194
Targeting death-inducing receptors in cancer therapy
Takeda, K., Stagg, J., Yagita∥, H., Okumura, K., & Smyth, M. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210374 · Cited by 187
B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells
Hurchla, M. A., Šedý, J. R., Gavrieli, M., Drake, C. G., Murphy, T. L., & MURPHY, K. M. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3377 · Cited by 185
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Dávila, E., Kennedy, R. B., & Celis, E. (2003) · PubMed · Cited by 181
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling
Evel-Kabler, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26169 · Cited by 180
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Zhao, Y., Yang, W., Huang, Y., Cui, R., Li, X., & Li, B. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490025 · Cited by 182
Immunosuppressive role of semaphorin‐3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization
Lepelletier, Y., Moura, I. C., Hadj-Slimane, R., Renand, A., Susana Fiorentino, G., Baude, C., Shirvan, A., Barzilai, A., & Hermine, O. (2006) · European Journal of Immunology · doi:10.1002/eji.200535601 · Cited by 178
Cancer immunotherapy
Baxevanis, C. N., Perez, S. A., & Papamichail, M. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360902937809 · Cited by 183
Electroporation-Enhanced Nonviral Gene Transfer for the Prevention or Treatment of Immunological, Endocrine and Neoplastic Diseases
Prud’homme, G. J., Glinka, Y., Khan, A. S., & Draghia, R. (2006) · Current Gene Therapy · doi:10.2174/156652306776359504 · Cited by 176
Current genetic methodologies in the identification of disaster victims and in forensic analysis
Ziętkiewicz, E., Witt, M. M., Daca‐Roszak, P., Żebracka‐Gala, J., Goniewicz, M., Jarząb, B., & Witt, M. (2011) · Journal of Applied Genetics · doi:10.1007/s13353-011-0068-7 · Cited by 174
B7-H3 role in the immune landscape of cancer.
Castellanos, J. R., Purvis, I. J., Labak, C. M., Guda, M. R., Tsung, A. J., Velpula, K. K., & Asuthkar, S. (2017) · Europe PMC (PubMed Central) · Cited by 172
Inhibitory Receptors on Lymphocytes: Insights from Infections
Odorizzi, P. M., & Wherry, E. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100038 · Cited by 175
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
Page, D. B., Yuan, J. D., Redmond, D., Wen, Y. H., Durack, J. C., Emerson, R., Solomon, S. B., Dong, Z., Wong, P., Comstock, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0013 · Cited by 168
Self-citation
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
Redmond, W. L., Linch, S. N., & Kasiewicz, M. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0031-t · Cited by 174
Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
Sun, T., Zhou, Y., Yang, M., Hu, Z., Tan, W., Han, X., Shi, Y., Yao, J., Guo, Y., Yu, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0806 · Cited by 167
A new era of cancer phototherapy: mechanisms and applications
Wang, Y., Ma, K., Kang, M., Yan, D., Niu, N., Yan, S., Sun, P., Zhang, L., Sun, L., Wang, D., et al. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00708e · Cited by 162
The Role of Antigen Spreading in the Efficacy of Immunotherapies
Brossart, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0305 · Cited by 165
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 163
Improving cancer immunotherapy by targeting tumor-induced immune suppression
Stewart, T. J., & Smyth, M. J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9280-5 · Cited by 152
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
Herrmann, A., Priceman, S. J., Kujawski, M., Xin, H., Cherryholmes, G. A., Zhang, W., Zhang, C., Lahtz, C., Kowolik, C. M., Forman, S. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73174 · Cited by 156
α-CTLA-4 mAb-associated Panenteritis
Oble, D. A., Mino-Kenudson, M. A., Goldsmith, J. D., Hodi, F. S., Seliem, R. M., Dranoff, G., Mihm, M. C., Hasserjian, R. P., & Lauwers, G. Y. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31817150e3 · Cited by 151
Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics
Han, X., Li, H., Zhou, D. R., Chen, Z., & Gu, Z. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00339 · Cited by 151
Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer
Loos, M., Giese, N. A., Kleeff, J. H., Giese, T., Gaida, M. M., Bergmann, F., Laschinger, M., Büchler, M. W., & Frieß, H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.056 · Cited by 151
The genetic legacy of western Bantu migrations
Beleza, S. S., Gusmão, L., Amorim, A., Carracedo, Á., & Salas, A. (2005) · Human Genetics · doi:10.1007/s00439-005-1290-3 · Cited by 150
HLA Class II Locus and Susceptibility to Podoconiosis
Ayele, F. T., Adeyemo, A., Finan, C., Hailu, E., Sinnott, P. J., Burlinson, N. D., Aseffa, A., Rotimi, C. N., Newport, M. J., & Davey, G. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108448 · Cited by 150
Adenosine Receptors and Cancer
Fishman, P., Bar‐Yehuda, S., Synowitz, M., Powell, J. D., Klotz, K., Gessi, S., & Borea, P. A. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_14 · Cited by 158
Cytotoxic T-Lymphocyte–Associated Antigen-4
Salama, A. K. S., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2232 · Cited by 149
Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment
Xie, Q., Ding, J. P., & Chen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.027 · Cited by 155
Nature, nurture and human disease
Chakravarti, A., & Little, P. (2003) · Nature · doi:10.1038/nature01401 · Cited by 148
Signaling Through OX40 Enhances Antitumor Immunity
Jensen, S. M., Maston, L. D., Gough, M. J., Ruby, C. E., Redmond, W. L., Crittenden, M. R., Li, Y., Puri, S., Poehlein, C. H., Morris, N. P., et al. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.013 · Cited by 146
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 152
Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome
Bennet, S., Öhman, L., & Simrén, M. (2015) · Gut and Liver · doi:10.5009/gnl14344 · Cited by 144
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hayashi, H., & Nakagawa, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01548-1 · Cited by 144
Changing the paradigm from 'race' to human genome variation
Royal, C. D. M., & Dunston, G. M. (2004) · Nature Genetics · doi:10.1038/ng1454 · Cited by 142
Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma
Tirapu, I., Huarte, E., Guiducci, C., Arina, A., Zaratiegui, M., Murillo, O., González, Á., Berasain, C., Berraondo, P., Fortes, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1681 · Cited by 146
Multiple Costimulatory Modalities Enhance CTL Avidity
Hodge, J. W., Chakraborty, M., Kudo‐Saito, C., Garnett‐Benson, C., & Schlom, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.5994 · Cited by 138
Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
Madan, R. A., Gulley, J. L., Fojo, T., & Dahut, W. L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0129 · Cited by 138
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
Lee, Y. H., Tai, D. W.-M., Yip, C., Choo, S. P., & Chew, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568759 · Cited by 139
An innately interesting decade of research in immunology
Germain, R. N. (2004) · Nature Medicine · doi:10.1038/nm1159 · Cited by 136
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3243 · Cited by 135
Self-citation
Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen
Tang, Y., Lou, J., Alpaugh, R. K., Robinson, M. K., Marks, J. D., & Weiner, L. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2815 · Cited by 135
Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
Keler, T., Halk, E., Vitale, L. A., O’Neill, T., Blanset, D. L., Lee, S., Srinivasan, M., Graziano, R. F., Davis, T. A., Lönberg, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6251 · Cited by 134
Progress on new vaccine strategies against chronic viral infections
Berzofsky, J. A., Ahlers, J. D., Janik, J. E., Morris, J., Oh, S., Terabe, M., & Belyakov, I. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22674 · Cited by 133
Minor H Antigen HA-1–specific Regulator and Effector CD8+ T Cells, and HA-1 Microchimerism, in Allograft Tolerance
Cai, J., Lee, J., Jankowska−Gan, E., Derks, R. A., Pool, J., Mutis, T., Goulmy, E., & Burlingham, W. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031012 · Cited by 132
Negative Regulation of T Cell Receptor–Lipid Raft Interaction by Cytotoxic T Lymphocyte–associated Antigen 4
Chikuma, S., Imboden, J. B., & Bluestone, J. A. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021646 · Cited by 129
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
Robert, C., & Ghiringhelli, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0028 · Cited by 128
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia
Shen, W., Patnaik, M. M., Ruiz, A. J., Russell, S. J., & Peng, K.-W. (2015) · Blood · doi:10.1182/blood-2015-06-652503 · Cited by 130
Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
Chan, D. V., Gibson, H. M., Aufiero, B. M., Wilson, A. J., Hafner, M. S., Mi, Q.-S., & Wong, H. K. (2013) · Genes and Immunity · doi:10.1038/gene.2013.57 · Cited by 130
Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis
Kim, D.-H., Park, H., Lim, S., Koo, J., Lee, H., Choi, J. O., Oh, J. H., Ha, S.-J., Kang, M., Lee, C. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02731-6 · Cited by 129
Immune Activation Driven by CTLA-4 Blockade Augments Viral Replication at Mucosal Sites in Simian Immunodeficiency Virus Infection
Cecchinato, V., Tryniszewska, E. A., Ma, Z. M., Vaccari, M., Boasso, A., Tsai, W.-P., Petrovas, C., Fuchs, D., Héraud, J., Venzon, D. J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5439 · Cited by 127
Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence
Ma, X., Zhang, B., & Zheng, W. (2013) · Gut · doi:10.1136/gutjnl-2012-304121 · Cited by 125
Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine
He, Y., Zhang, G., Wang, X., Zhang, H., Yuan, Y., Li, D., & Feng, Z. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4919 · Cited by 125
THE ECOLOGIES OF HUMAN IMMUNE FUNCTION
McDade, T. W. (2005) · Annual Review of Anthropology · doi:10.1146/annurev.anthro.34.081804.120348 · Cited by 124
Memory T cells need CD28 costimulation to remember
Boesteanu, A. C., & Katsikis, P. D. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.02.005 · Cited by 128
Preferential contribution of B7‐H1 to programmed death‐1‐mediated regulation of hapten‐specific allergic inflammatory responses
Tsushima, F., Iwai, H., Otsuki, N., Abe, M., Hirose, S., Yamazaki, T., Akiba, H., Yagita∥, H., Takahashi, Y., Omura, K., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324084 · Cited by 125
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result
Jiang, M., Sun, D., Guo, Y., Guo, Y., Xiao, J., Wang, L., & Yao, X. (2019) · Academic Radiology · doi:10.1016/j.acra.2019.04.016 · Cited by 122
TKIs in combination with immunotherapy for hepatocellular carcinoma
Stefanini, B., Ielasi, L., Chen, R., Abbati, C., Tonnini, M., Tovoli, F., & Granito, A. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2181162 · Cited by 120
Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies
Yasmeen, F., Pirzada, R. H., Ahmad, B., Choi, B., & Choi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147666 · Cited by 131
CD4 regulatory T cells in human cancer pathogenesis
Knutson, K. L., Disis, M. L., & Salazar, L. G. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0194-y · Cited by 122
Sensors of ionizing radiation effects on the immunological microenvironment of cancer
Demaria, S., & Formenti, S. C. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701481816 · Cited by 122
IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain—containing protein tyrosine phosphatase 1
Taylor, A., Akdiş, M., Joss, A., Akkoç, T., Wenig, R., Colonna, M., Daigle, I., Flory, E., Blaser, K., & Akdiş, C. A. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.004 · Cited by 119
Skin Reactions in a Subset of Patients With Stage IV Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen 4 Monoclonal Antibody as a Single Agent
Jaber, S. H., Cowen, E. W., Haworth, L. R., Booher, S. L., Berman, D. M., Rosenberg, S. A., & Hwang, S. T. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.2.166 · Cited by 119
Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4
Mo, X., Zhang, H., Preston, S., Martin, K. A., Zhou, B., Vadalia, N., Gamero, A. M., Soboloff, J., Tempera, I., & Zaidi, M. R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1615 · Cited by 125
Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy
Zhao, H., Xu, J., Li, Y., Guan, X., Han, X., Xu, Y., Zhou, H., Peng, R., Wang, J., & Liu, Z. (2019) · ACS Nano · doi:10.1021/acsnano.9b05974 · Cited by 118
The Role of CD276 in Cancers
Liu, S., Liang, J., Liu, Z., Zhang, C., Wang, Y., Watson, A. H., Zhou, C., Zhang, F., Wu, K., Zhang, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.654684 · Cited by 119
Local Release of Highly Loaded Antibodies from Functionalized Nanoporous Support for Cancer Immunotherapy
Lei, C., Liu, P., Chen, B., Mao, Y., Engelmann, H. E., Shin, Y., Jaffar, J., Hellström, I., Liu, J., & Hellström, K. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102414t · Cited by 117
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wang, W., Yu, D., Sarnaik, A. A., Yu, B., Hall, M. S., Morelli, D., Zhang, Y., Zhao, X., & Weber, J. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-146 · Cited by 122
Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy
Cao, X., Chen, J., Li, B., Dang, J., Zhang, W., Zhong, X., Wang, C., Raoof, M., Sun, Z., Yu, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl9171 · Cited by 120
Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format
Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120
Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways
Ware, C. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00629.x · Cited by 119
Signal pathways and precision therapy of small-cell lung cancer
Yuan, M., Zhao, Y., Arkenau, H., Lao, T., Chu, L., & Xu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01013-y · Cited by 117
Harnessing the immune system in acute myeloid leukaemia
Austin, R. J., Smyth, M. J., & Lane, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.020 · Cited by 114

Authors: Egen, J. G., Kuhns, M. S., & Allison, J. P.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Allison, James P.
ORCID: Egen, Jackson G.
Kuhns, Michael S.
Allison, James P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-07
Volume: 3
Issue: 7
Pages: 611-618
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni0702-611
OpenAlex: W2140460887
Cited by: 940
References: 93
Citations by year: 2026: 10 · 2025: 15 · 2024: 30 · 2023: 34 · 2022: 45 · 2021: 50 · 2020: 43 · 2019: 33 · 2018: 27 · 2017: 36 · 2016: 28 · 2015: 32 · 2014: 31 · 2013: 38 · 2012: 25
FWCI: 5.88
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (CA40041, R01CA057986, CA57986)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, costimulatory receptors, CD28, T cell activation, T cell receptor signaling, T cell regulation, cancer immunotherapy, CTLA-4 blockade, immune checkpoint blockade
MeSH terms: Abatacept, Animals, Antigens, Differentiation, Cell Division, Colonic Neoplasms, Disease Models, Animal, Fibrosarcoma, Gene Expression Regulation, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antigens, CD, Immunoconjugates, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks